Dawn Trueman

AstraZeneca

H指数:6

被引数:465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

下一代口服选择性雌激素受体降解剂Camizestrant (AZD9833) 抑制ER乳腺癌生长并克服内分泌和CDK4/6抑制剂抗性

CANCER RESEARCH

IF16.6

2023-09-1916

OAAI

Lawson, Mandy; Cureton, Natalie; Ros, Susana; Cheraghchi-Bashi, Azadeh; Urosevic, Jelena; D'Arcy, Sophie; Delpuech, Oona; Dupont, Michelle; Fisher, David I.; Gangl, Eric T.; Lewis, Hilary; Trueman, Dawn; Wali, Neha; Williamson, Stuart C.; Moss, Jennifer; Montaudon, Elodie; Derrien, Heloise; Marangoni, Elisabetta; Miragaia, Ricardo J.; Gagrica, Sladjana; Morentin-Gutierrez, Pablo; Moss, Thomas A.; Maglennon, Gareth; Sutton, Daniel; Polanski, Radoslaw; Rosen, Alan; Cairns, Jonathan; Zhang, Pei; Sanchez-Guixe, Monica; Serra, Violeta; Critchlow, Susan E.; Scott, James S.; Lindemann, Justin P. O.; Barry, Simon T.; Klinowska, Teresa; Morrow, Christopher J.; Carnevalli, Larissa

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-02-0211

PRE

Scott, James S.; Stead, Darren; Barlaam, Bernard; Breed, Jason; Carbajo, Rodrigo J.; Chiarparin, Elisabetta; Cureton, Natalie; Davey, Paul R. J.; Fisher, David I.; Gangl, Eric T.; Grebe, Tyler; Greenwood, Ryan D.; Hande, Sudhir; Hatoum-Mokdad, Holia; Hughes, Samantha J.; Hunt, Thomas A.; Johnson, Tony; Kavanagh, Stefan L.; Klinowska, Teresa C. M.; Larner, Carrie J. B.; Lawson, Mandy; Lister, Andrew S.; Longmire, David; Marden, Stacey; McGuire, Thomas M.; McMillan, Caroline; McMurray, Lindsay; Morrow, Christopher J.; Nissink, J. Willem M.; Moss, Thomas A.; O'Donovan, Daniel H.; Polanski, Radoslaw; Stokes, Stephen; Thakur, Kumar; Trueman, Dawn; Truman, Caroline; Tucker, Michael J.; Wang, Haixia; Whalley, Nicky; Wu, Dedong; Wu, Ye; Yang, Bin; Yang, Wenzhan

Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

CANCER RESEARCH

IF16.6

2020-08-151

PRE

Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

CANCER RESEARCH

IF16.6

2020-08-152

PRE

Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

CANCER RESEARCH

IF16.6

2020-02-150

PRE

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

MOLECULAR CANCER THERAPEUTICS

IF5.5

2017-06-0133

OAAI

Continuous, low intensity systemic dosing maximizes the therapeutic margin of Eg5/KSP inhibition in an orthotopic model of urothelial cell carcinoma

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2016-02-10168

OAAI

Ashton, Susan; Song, Young Ho; Nolan, Jim; Cadogan, Elaine; Murray, Jim; Odedra, Rajesh; Foster, John; Hall, Peter A.; Low, Susan; Taylor, Paula; Ellston, Rebecca; Polanska, Urszula M.; Wilson, Joanne; Howes, Colin; Smith, Aaron; Goodwin, Richard J. A.; Swales, John G.; Strittmatter, Nicole; Takats, Zoltan; Nilsson, Anna; Andren, Per; Trueman, Dawn; Walker, Mike; Reimer, Corinne L.; Troiano, Greg; Parsons, Donald; De Witt, David; Ashford, Marianne; Hrkach, Jeff; Zale, Stephen; Jewsbury, Philip J.; Barry, Simon T.

Establishment of an orthotopic bladder cancer model to evaluate continuous intravesical delivery of small molecule inhibitors in the nude rat

CANCER RESEARCH

IF16.6

2015-08-011

PRE

AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index

CANCER RESEARCH

IF16.6

2014-10-011

PRE

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

MOLECULAR CANCER THERAPEUTICS